Public administration and R&D localisation by pharmaceutical and biotech companies: A theoretical framework and the Italian case-study

Health Policy

Volumn 81, Issue 1, 2007, Pages 117-130

  Jommi, Claudio ^a   Paruzzolo, Silvia ^a  

^a CERGAS   (Italy)

Author keywords

Biotechnologies; Business government relationships; Pharmaceuticals; Public policy; R D

Indexed keywords

ARTICLE; BIOTECHNOLOGICAL PRODUCTION; CASE STUDY; CONCEPTUAL FRAMEWORK; DRUG INDUSTRY; FINANCIAL MANAGEMENT; INFORMATION RETRIEVAL; INTERVIEW; INVESTMENT; METHODOLOGY; ORGANIZATION AND MANAGEMENT; POLICY; SOCIAL SECURITY;

BIOTECHNOLOGY; COMMERCE; FEDERAL GOVERNMENT; INTERVIEWS; ITALY; ORGANIZATIONAL CASE STUDIES; PUBLIC POLICY; RESEARCH;

EID: 33847270273     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2006.05.010     Document Type: Article

References (35)

1. Emilien G. Future European health care: cost containment, health care reform and scientific progress in drug research. International Journal of Health Planning and Management 12 Issue 2 (1997) 81-101
2. DiMasi J., Hansen R.W., and Grabowski H.G. The price of innovation: new estimates of drug development costs. Journal of Health Economics 22 (2003) 151-185
3. Light DW. Bush declares war on European drug prices [unpublished].
4. Riggs T.L. Research and development costs. Lancet 363 (2004) 184
5. Gambardella A, Orsenigo L, Pammolli F. Global competitiveness in pharmaceutical: a European perspective. Report prepared for the Enterprise Directorate General of the European Commission. Luxembourg: European Communities; 2001
6. Farmindustria. Indicatori Farmaceutici. Roma: Farmindustria; 2005.
7. Strauss A., and Corbin J. Basics of qualitative research techniques and procedures for developing a grounded theory. 2nd ed. (1998), Sage Publication, London
8. Berg B.L. Qualitative research methods for the social sciences (2001), Allyn and Bacon, Boston
9. Stewart D.W., and Shamdasani P.N. Focus groups: theory and practice (1990), Sage Publications, Thousand Oaks, CA
10. Patton M.Q. Qualitative evaluation and research methods. 2nd ed. (1990), Sage Publications, Newbury Park, CA
11. Belderbos R, Lykogianni E, Veugelers R. Strategic R&D location by multinational firms: spillovers, technology sourcing and competition. Paper prepared for 2005 EARIE Conference; 2005.
12. Hanker L. Regulating for competition. Government, law and the pharmaceutical industry in the UK and France (1990), Clarendon Press, Oxford
13. Thomas L.G. Implicit industrial policy: the triumph of Britain and the failure of France in the global pharmaceuticals. Industrial and Corporate Change 3 2 (1994) 451-490
14. Camper S, Matraves C. Institutional frameworks and innovation in the German and UK pharmaceutical industry. Research Policy 2003;32:1865-79.
15. McKelvey M., Rickne A., and Laage-Hellman J. The economic dynamics of modern biotechnology (2004), Edward Elgar Publishing, Northampton
16. Jommi C. Pharmaceutical policy and organisation of the regulatory authorities in the main EU countries (2001), Egea, Milano
17. Cave M., and Towse A. Regulating prices paid by the NHS for medicines supplied by the UK-based pharmaceutical industry (1997), OHE Briefing, Office of Health Economics, London
18. Mossialos E., and Mrazek M. Entrepreneurial behaviour in pharmaceutical markets and the effects of regulation. In: Saltman R., Busse R., and Mossialos E. (Eds). Regulating entrepreneurial behaviour in health care markets (2002), Open University Press, Oxford 146-162
19. Grund J. The societal value of pharmaceuticals balancing industrial and healthcare policy. Pharmacoeconomics 10 Issue 1 (1996) 14-22
20. Danzon P. Pharmaceutical price regulation: national policies versus global interests (1997), The AEI Press, Washington
21. Vogel R.J. Pharmaceutical patents and price controls. Clinical Therapeutics 7 (2002) 1204-1222
22. Bloom N., and Van Reenen J. Regulating drug prices: where do we go from here?. Fiscal Studies 19 3 (1998) 321-342
23. In: Green G. (Ed). Should pharmaceutical price be regulated? The strengths and weaknesses of the British NHS (1997), IEA, London
24. Mitchell W., Roehl T., and Slattery R.J. Influences on R&D growth among Japanese pharmaceutical firms. Journal of High Technology Management Research 6 1 (1995) 17-31
25. Barrell R., and Nigel P. Domestic institutions, agglomerations and foreign investment in Europe. European Economic Review 43 (1999) 9925-9934
26. Arora A., and Gambardella A. The changing technology of technical change: general and abstract knowledge and the division of innovative labour. Research Policy 23 (1994) 523-532
27. Breschi S. The geography of innovation: a cross sector analysis. Regional Studies 34 (2000) 213-229
28. Zucker L, Darby M, Brewer M. Intellectual human capital and the birth of US biotechnology enterprises. National Bureau of Economic Research. Working Paper 4653. Cambridge: NBER, 1994.
29. Mooney K.G. Challenges faced by the pharmaceutical industry: training graduates for employment in pharmaceutical R&D. European Journal of Pharmaceutical Sciences 12 (2001) 353-359
30. Ministère de l'Economie, des finances et de l'industrie. Renforcer l'attractivite del la France pour l'industrie pharmaceutique innovante. Paris: Ministère de l'Economie, des finances et de l'industrie, Conseil Général des Mines; 2003.
31. In: Cipollina L. (Ed). L'innovazione farmaceutica nel contesto internazionale: scenari, prospettive e politiche di incentivazione (2004), Il Sole 24 Ore, Milano
32. Dasgupta P., and David P.A. The new economics of science. Research Policy 23 (1994) 23-41
33. Piscitello L. La localizzazione delle attività innovative delle grandi imprese multinazionali nelle regioni europee. Tendenza all'agglomerazione, spillovers ed altre esternalità territoriali. Paper Gruppo di studio CNR Sviluppo e integrazione economica internazionale: fallimenti del mercato e ruolo delle istituzioni. Ancona 17-18 November; 2000.
34. Chiesa V. La bioindustria: strategie competitive e organizzazione industriale nel settore delle biotecnologie farmaceutiche (2003), Etas, Parma
35. Jommi C. L'Agenzia Italiana del Farmaco: peculiarità rispetto al contesto europeo ed ai processi di modernizzazione della pubblica amministrazione. Economia e politica del farmaco 3 (2004) 11-16